Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Novocure Ltd
NASDAQ NVCR
Data sourced from
and
and
Novocure Ltd EBIT to Fixed Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2024: -0.40
Novocure Ltd EBIT to Fixed Assets Ratio is -0.40 for the Trailing 12 Months (TTM) ending March 31, 2024, a 29.93% change year over year. The EBIT to Fixed Assets Ratio measures a company's operating earnings (EBIT) generated per dollar of fixed assets (property, plant, and equipment). It indicates how efficiently a company utilizes its fixed assets to generate earnings. A higher ratio suggests better earnings generation from fixed assets, indicating improved operational efficiency and potentially higher profitability.
-
Novocure Ltd EBIT to Fixed Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was -0.57, a -126.34% change year over year.
-
Novocure Ltd EBIT to Fixed Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was -0.25, a -222.42% change year over year.
-
Novocure Ltd EBIT to Fixed Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 0.21, a 1,287.17% change year over year.
-
Novocure Ltd EBIT to Fixed Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2020 was -0.02, a 95.82% change year over year.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: NVCR
| CEO | Mr. William F. Doyle |
| IPO Date | Oct. 2, 2015 |
| Location | Jersey |
| Headquarters | No. 4 The Forum, Saint Helier, Jersey, JE2 4UF |
| Employees | 1,453 |
| Sector | Healthcare |
| Industry | Medical devices |
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Key trends
Similar companies
InMode Ltd
NA
NA
iRhythm Technologies Inc
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email